secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001846253-23-000024
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb Q4 revenue $35.3M, net income $6.8M; record 13 new partnerships in 2022
------------------------------------------------------------------------------

- Q4 revenue $35.3M (up from $15.3M YoY) driven by $25M TECVAYLI milestone; net income $6.8M vs loss of $3.1M.
- Full year 2022 revenue $59.1M (up from $34.7M); net loss $22.3M ($0.26/share) vs $27.0M loss in 2021.
- Cash and short-term investments $88.3M at Dec 31, 2022; received additional $35M in Jan 2023 from Janssen.
- Signed 13 new licenses in 2022; 26 OmniAb-derived programs in clinic/commercial; 291 total programs.
- Expects $10M milestone from TECVAYLI EU approval in 2023; 2023 year-end cash slightly higher than 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000184625323000024/0001846253-23-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000184625323000024/lgnd-20230330.htm
  HTML page:      https://secwatch.observer/filing/0001846253-23-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer